MUNDIPHARMA MEDICAL COMPANY LIMITED
Company Information
- Company Number
- 09273950
- Registered Address
- Unit 196 Cambridge Science Park, Milton Road, Cambridge, England, CB4 0AB
- Status
- Active
- Employee Count
- 106.0
- Turnover
- 426117000.0
- EBITDA
- 79793000.0
Additional Details
- Website
- https://mundipharma.com
- Company Type
- Private limited Company
- Incorporated On
- 21 October 2014
- Nature of Business
- 46460 - Wholesale of pharmaceutical goods
- Industries
- 0
- Region
- East of England
Company Location
Loading map...
Financial Metrics
Time to Pay
Payment Timeline
Payment Features
Payment Time Trends
Payment Distribution Trends
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2023 - 31 Dec 2023 | 31 Jan 2024 | 34 | 57% | 32% | 11% | 41% |
| 01 Jan 2023 - 30 Jun 2023 | 20 Jul 2023 | 33 | 58% | 31% | 11% | 31% |
| 01 Jul 2021 - 31 Dec 2021 | 30 Jan 2022 | 108 | 35% | 17% | 48% | 57% |
| 01 Jul 2021 - 31 Dec 2021 | 30 Jan 2022 | 43 | 38% | 50% | 13% | 64% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 77 | 30% | 37% | 32% | 60% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 90 | 31% | 27% | 42% | 70% |
| 01 Jan 2020 - 30 Jun 2020 | 30 Jul 2020 | 73 | 66% | 8% | 26% | 65% |
| 01 Jul 2019 - 31 Dec 2019 | 30 Jan 2020 | 48 | 53% | 27% | 21% | 36% |
| 01 Jan 2019 - 30 Jun 2019 | 24 Jul 2019 | 36 | 66% | 26% | 8% | 24% |
| 01 Jul 2018 - 31 Dec 2018 | 29 Jan 2019 | 32 | 77% | 17% | 6% | 17% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 33 | 73% | 20% | 7% | 23% |
Company Summary
MUNDIPHARMA MEDICAL COMPANY LIMITED is a global pharmaceutical company that is committed to developing and providing innovative and sustainable healthcare solutions
The company was founded in 1952 and has since expanded its operations to over 60 countries worldwide
The company's sustainability program focuses on reducing their environmental impact and promoting social responsibility
They have implemented various initiatives such as reducing their carbon footprint, promoting sustainable sourcing of materials, and supporting local communities through their corporate social responsibility projects
MUNDIPHARMA offers a wide range of prescription medicines, over-the-counter products, and medical devices in various therapeutic areas such as pain management, respiratory diseases, and oncology
Their products are developed using advanced technologies and are known for their high quality and effectiveness
The key people at MUNDIPHARMA include the CEO, Raman Singh, who has over 20 years of experience in the pharmaceutical industry, and the Chief Medical Officer, Dr
Gerd Zettlmeissl, who has a background in clinical research and development
To contact MUNDIPHARMA, individuals can visit their website at https://www.mundipharma.com/ or reach out to their registered office at Mundipharma House, Millbank, London SW1P 4QP, United Kingdom
The company also has various global offices and can be contacted through their local websites
Company Review
Trend Analysis
The average time taken for MUNDIPHARMA MEDICAL COMPANY LIMITED to pay invoices has been steadily increasing since 2018, with a sharp increase in 2020 and a slight decrease in 2021. This trend suggests that the company may be facing financial challenges or operational issues that are causing delays in invoice payments.
Volatility Analysis
The volatility in the percentage of invoices paid within 30 days has been relatively stable, with a slight decrease in 2021. However, the percentage of invoices paid later than 60 days has shown significant volatility, with a sharp increase in 2020 and a decrease in 2021. This indicates that the company may be struggling to maintain consistent payment terms with their suppliers.
Summary Analysis
Overall, MUNDIPHARMA MEDICAL COMPANY LIMITED has seen a decline in their ability to pay invoices on time. In 2018, the company was able to pay 73% of their invoices within 30 days, but by 2021, this number had dropped to 30%. This is a concerning trend that warrants further investigation.
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
The default position remains unchanged and is 90 days, however there may be changes to this default position on a case-by-case basis pending agreement with suppliers. On a case-by-case basis, payment terms to suppliers may be immediate payment or payment on terms within 7, 14, 30 or 60 days.
Were there any changes to the standard payment terms in the reporting period?
No
Any other information about payment terms
N/A
Maximum contractual payment period agreed
90
Dispute Resolution Process
As a supplier, if you have a query or dispute relating to a payment you believe is owed to you by MMCL, please email the following details below, to mmclaccounts.payable@mundipharma-sc.com a. Full supplier name, address; b. The name of your MMCL point of contact; c. Invoice number for the payment you are querying; d. Full details of your complaint; e. Upon receipt of all of the above details, MMCL commits to acknowledge receipt of your email within five working days, and may request further information to be able to respond in full; MMCL will investigate your query using the details provided and speak with relevant members of MMCL’s business, including members of MMCL’s legal department if necessary, and respond in full within 14 days of the date of MMCL’s acknowledgement to you.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
✅
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
